Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 7,073 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Mammary Cancer Clear all
Completed Phase 3 Interventional Results available

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

NCT03036488
View directory record Official record
Conditions
Triple Negative Breast Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Placebo, Granulocyte colony stimulating factor: Filgrastim or Pegfilgrastim
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
47
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 26, 2026, 10:03 PM EDT
Withdrawn No phase listed Observational

Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer

NCT01542203
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Study of NS-9 in Patients With Liver Metastases

NCT00094003
View directory record Official record
Conditions
Liver Neoplasms, Neoplasm Metastasis, Local Neoplasm Recurrences
Interventions
NS-9 [Poly I: Poly C]
Drug
Lead sponsor
NS Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
2
States / cities
Lebanon, New Hampshire • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2005 · Synced Oct 26, 2026, 10:03 PM EDT
Completed No phase listed Observational

Understanding Patient Perspectives on the Risks of Ionizing Radiation Used for Medical Imaging

NCT01482741
View directory record Official record
Conditions
Breast Cancer, Colon Cancer, Lung Cancer, Neuroblastoma, Testicular Cancer
Interventions
Focus Group Sessions
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2015 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Not applicable Interventional

Acupuncture in the Management of Post Operative Symptoms in Breast Cancer Patients

NCT00419822
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Sham Acupuncture, Patient to receive standard care without Acupuncture or Sham Acupuncture.
Procedure · Other
Lead sponsor
Legacy Health System
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 4, 2011 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Not applicable Interventional

Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

NCT03824145
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Lifestyle Intervention, Attention Control
Behavioral
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Maywood, Illinois • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Phase 3 Interventional

Fatigue Intervention Trial for Breast Cancer Survivors

NCT00513136
View directory record Official record
Conditions
Fatigue
Interventions
Group based mind body medicine intervention, Group-based mind body medicine intervention + family focus
Behavioral
Lead sponsor
Mercy Medical Center
Other
Eligibility
Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Results available

Quantitative Subharmonic Breast Imaging

NCT01490892
View directory record Official record
Conditions
Breast Cancer
Interventions
3D HI and SHI of UCA
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
La Jolla, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer

NCT02037542
View directory record Official record
Conditions
Weight
Interventions
Diet and exercise
Behavioral
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Oct 26, 2026, 10:03 PM EDT
Recruiting Phase 1 Interventional

A Study of PHST001 in Advanced Solid Tumors

NCT06840886
View directory record Official record
Conditions
Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
Interventions
PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI, FOLFOX, Gemcitabine, Mirvetuximab Soravtansine, Trastuzumab Deruxtecan
Biological · Drug
Lead sponsor
Pheast Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
20
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 26, 2026, 10:03 PM EDT
Completed No phase listed Observational

A Real-World Study of Early Breast Cancer Patients Eligible for Treatment With CDK4/6 Inhibitors

NCT07647042
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Not applicable Interventional

Docetaxel Plus Garlic in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT00079170
View directory record Official record
Conditions
Breast Cancer
Interventions
garlic, docetaxel
Dietary Supplement · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Exemestane With Celecoxib as Neoadjuvant Treatment in Postmenopausal Women With Stage II, III, and IV Breast Cancer

NCT00201773
View directory record Official record
Conditions
Breast Cancer
Interventions
Exemestane, Celecoxib, Correlative studies
Drug · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integration of Cancer Health Activities Into African American Churches

NCT03178383
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Colorectal Cancer
Interventions
Project HEAL, Project HEAL 2.0
Behavioral
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years and older
Enrollment
446 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 26, 2026, 10:03 PM EDT
Terminated No phase listed Observational

Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy

NCT03393741
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Taxane, Vinorelbine, Ixabepilone, Eribulin, Chemotherapy
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Results available

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

NCT01209195
View directory record Official record
Conditions
Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,, Primary Peritoneal Cancer or Endometrial Cancer, Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Interventions
MM-121, Paclitaxel
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
5
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Not applicable Interventional Results available

Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer

NCT02419807
View directory record Official record
Conditions
Stage I Breast Cancer, Stage II Breast Cancer
Interventions
Indocyanine Green Solution, Technetium Tc-99m Sulfur Colloid, Lymphoscintigraphy, Axillary Lymph Node Biopsy
Drug · Radiation · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 26, 2026, 10:03 PM EDT
Terminated Not applicable Interventional

Flexitouch Lymphedema System in Treating Stage II Lymphedema in Patients With Breast Cancer

NCT01019512
View directory record Official record
Conditions
Breast Cancer, Lymphedema
Interventions
questionnaire administration, lymphedema management
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Oct 26, 2026, 10:03 PM EDT
Recruiting Not applicable Interventional

Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors

NCT07120100
View directory record Official record
Conditions
Breast Cancer Female, Gynecologic Cancer
Interventions
rTMS
Device
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 26, 2026, 10:03 PM EDT
Completed No phase listed Observational

Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer

NCT00897702
View directory record Official record
Conditions
Breast Cancer
Interventions
Blood draw, immunoenzyme technique, biopsy, histopathologic examination
Other · Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Phase 2 Interventional

Evaluating Patient Information Prescriptions

NCT00355381
View directory record Official record
Conditions
Breast Neoplasms, Premature Birth
Interventions
Information Services (IRx)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 26, 2026, 10:03 PM EDT
Terminated No phase listed Observational

Patient Registry: Partial Breast Irradiation

NCT01127971
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
19 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Green Bay, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

NCT02270372
View directory record Official record
Conditions
Advanced Breast Carcinoma, Advanced Ovarian Carcinoma
Interventions
ONT-10, Varlilumab combination
Biological
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Birmingham, Alabama • Aurora, Colorado • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 26, 2026, 10:03 PM EDT
Completed Phase 1 Interventional

A Study of PRT1419 in Patients With Advanced Solid Tumors

NCT04837677
View directory record Official record
Conditions
Sarcoma, Melanoma, Lung Cancer, Breast Cancer, Esophageal Cancer, Cervical Cancer, Head and Neck Cancer
Interventions
PRT1419
Drug
Lead sponsor
Prelude Therapeutics Incorporated
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Denver, Colorado • Lake Mary, Florida • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 26, 2026, 10:03 PM EDT